Early access to immunotherapy and chemotherapy for anal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial provides access to a combination of an immunotherapy drug (retifanlimab) with two chemotherapy drugs (carboplatin and paclitaxel) for people with a certain type of anal cancer that has spread or cannot be removed. The goal is to see if this treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have squamous cell carcinoma of the anal canal that has spread or cannot be removed by surgery.
- You have not had immunotherapy (a type of treatment that helps your immune system fight cancer) before.
- If you had previous treatments like radiation or chemotherapy, you must have recovered from their side effects.
- You must be generally active and able to care for yourself.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of new and existing drugs, followed by chemoradiotherapy with immunotherapy, for people with locally advanced squamous cell carcinoma of the anal canal. It aims to see if this approach is safe and effective.
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
This trial tests a combination of the immunotherapy drug pembrolizumab, two chemotherapy drugs (carboplatin and paclitaxel), and radiation for people with early-stage anal cancer who cannot take the usual chemotherapy. The goal is to see if this approach is safe and effective as an alternative treatment.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with advanced anal cancer that has spread or come back. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Squamous Cell Carcinoma of the Anal Canal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.